Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation

Google, Apollo Partnership Progresses

 
• By Vibha Ravi

Machines are now generating molecules that “no human would have imagined,” heard delegates at the BioAsia 2024 summit in Hyderabad, as big pharma and tech leaders discussed the many ways in which AI is causing fundamental shift in R&D approaches.  

BioAsia 2024 Healthtech panel
L to R - Sangita Reddy - Joint MD, Apollo Hospitals; Phani Mitra – CDIO, Dr. Reddy's; Scott Burgett – Director, Garmin Health; Greg Meyers – EVP, CDTO, Bristol Myers; Diogo Rau - EVP, CIDO, Eli Lilly; Sriram Rajamani -Corporate VP, MD Microsoft Research India; Jeremy Jurgens - MD World Economic Forum • Source: BioAsia, Government of Telangana, India

More from AI

More from Digital Technologies